Click here to BLOCK YOUR CONTENT SPACE IN OUR NEXT ISSUES |
|
![](https://www.worldpharmatoday.com/images/article/Weekly_newsletter/comman_images/6.png) |
Latest News and Updates |
|
|
|
|
Drug Launch Prices Have Gone Up 20% Yearly For A Decade
Study confirms recent launches of complex biologics and medications for rare diseases, which merit higher costs, but does not explain the average price hike.
|
|
|
| |
|
To Be The Global Pharmacy India Must Detach From China First
India has launched an ambitious effort to reducing its reliance on China for the essential raw materials as part of its drive to becoming the worlds pharmacy.
|
|
![](https://www.worldpharmatoday.com/wp-content/uploads/techno-trends/9798/pharma_market_growth-696x393.jpg) |
| |
| |
|
|
|
ICMR Gives Guidelines For Drones To Deliver Medical Supplies
ICMR has put in place the guidelines to use drones as an option for delivering medical supplies with what items to deliver, where to take-off and land, etc.
|
|
|
| |
|
New Drug Mix From ICR And The Royal Marsden Shows Promise
Early phase clinical trial of new drug mix shows positive outcomes against the mutant variants of the KRAS gene called the Death Star as it cannot be breached.
|
|
![](https://www.worldpharmatoday.com/wp-content/uploads/news/17700/ab-science-696x394.jpg) |
|
|
| |
|
|
|
Each Patient In The Clinical Study Sees The Cancer Vanish
Dostarlimab is a drug which was administered across all the 18 rectal cancer patients, and the cancer was entirely eradicated as a result of the treatment.
|
|
|
| |
|
Lunsumio, Blood Cancer Drug By Roche Gets Global Approval
Post the patent expiration of Rituxan, pharmaceutical giant Roche is looking out to add new blood cancer drugs to its portfolio as lymphoma gets its clearance.
|
|
![](https://www.worldpharmatoday.com/wp-content/uploads/news/22996/roches-bispecific-blood-cancer-drug-lunsumio-696x398.jpg) |
| |
| |
|
|
|
FDA Says It Must Assess Novavax COVID-19 Production Changes
The FDA has indicated that it will be required to give its stamp of approval to the recent alterations that Novavax made to its vaccine manufacturing process.
|
|
|